Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Fig. 5

C44-Fc suppresses ANGPTL3-induced blockade of LPL. The vertical axis indicates the incremental concentrations of four kinds of ANGPTL3 proteins or antibody including of C44-Fc, evinacumab and control Ab (n = 3). The vertical axis indicates the relative fluorescence units (RFU) at 482/515 nm (excitation/emission)

Back to article page